📊 ALGS Key Takeaways
Is Aligos Therapeutics, Inc. (ALGS) a Good Investment?
Aligos Therapeutics is a pre-revenue stage biopharmaceutical company with severe cash burn and minimal revenue generation, indicating the pipeline has not yet achieved meaningful commercialization. The company is burning cash at an unsustainable rate ($82.6M negative free cash flow annually) while maintaining only $18.3M in cash reserves, creating critical liquidity concerns within 3-6 months. Without evidence of clinical success or revenue inflection, the company faces existential risk despite reasonable balance sheet leverage.
Aligos Therapeutics shows very weak fundamentals: minimal revenue, extremely negative operating and net margins, and deeply negative free cash flow. While the latest net loss improved year over year and the balance sheet has no long-term debt, the cash balance appears small relative to the annual operating cash burn, making funding risk and dilution risk the central fundamental concerns.
Why Buy Aligos Therapeutics, Inc. Stock? ALGS Key Strengths
- Strong current ratio of 3.90x provides near-term liquidity cushion
- Zero long-term debt reduces financial leverage and restructuring risk
- Stockholders equity of $53.5M provides some asset base for potential reorganization
- 4 Form 4 insider filings in last 90 days suggest active management engagement
- Debt-free capital structure reduces financial leverage risk
- Current ratio and quick ratio of 3.90x indicate near-term liabilities are manageable
- Year-over-year improvement in net income and EPS suggests reported losses narrowed
ALGS Stock Risks: Aligos Therapeutics, Inc. Investment Risks
- Negative operating cash flow of $82.5M with only $18.3M cash on hand implies runway of ~2-3 months without additional capital raises
- Net margin of -1106.7% and operating margin of -4024.9% demonstrate business model failure at current stage
- Revenue of $2.2M flat YoY indicates no commercial traction despite being a public company
- Sustained negative free cash flow of $82.6M annually is economically unsustainable without continuous dilutive financing
- Pre-revenue biotech with massive losses suggests pipeline failures or delayed market adoption
- Revenue base is too small to support the cost structure, with operating margin at -4024.9%
- Operating cash flow of -$82.50M versus cash of $18.30M implies limited cash runway without new financing
- Improvement in net income quality is questionable because core operations remain deeply unprofitable
Key Metrics to Watch
- Monthly cash burn rate and projected cash runway length
- Clinical trial progression and regulatory approval milestones for pipeline candidates
- Quarterly revenue growth and gross margin achievement from any commercialized products
- Capital raise announcements and dilution percentage from future equity issuances
- Cash runway relative to quarterly operating cash burn
- Pipeline progress translating into collaboration revenue, milestone payments, or meaningful expense reduction
Aligos Therapeutics, Inc. (ALGS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.90x current ratio provides a solid financial cushion.
ALGS Profit Margin, ROE & Profitability Analysis
ALGS vs Healthcare Sector: How Aligos Therapeutics, Inc. Compares
How Aligos Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aligos Therapeutics, Inc. Stock Overvalued? ALGS Valuation Analysis 2026
Based on fundamental analysis, Aligos Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aligos Therapeutics, Inc. Balance Sheet: ALGS Debt, Cash & Liquidity
ALGS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aligos Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-20.94 indicates the company is currently unprofitable.
ALGS Revenue Growth, EPS Growth & YoY Performance
ALGS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $741.0K | -$4.3M | $-0.44 |
| Q2 2025 | $965.0K | $5.1M | $0.81 |
| Q1 2025 | $311.0K | -$34.9M | $-2.11 |
| Q3 2024 | $1.1M | -$18.0M | $-3.07 |
| Q2 2024 | $1.1M | $5.1M | $0.03 |
| Q1 2024 | $140.0K | -$23.0M | $-0.22 |
| Q3 2023 | N/A | -$18.0M | $-0.41 |
| Q2 2023 | N/A | -$18.8M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aligos Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALGS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aligos Therapeutics, Inc. (CIK: 0001799448)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALGS
What is the AI rating for ALGS?
Aligos Therapeutics, Inc. (ALGS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALGS's key strengths?
Claude: Strong current ratio of 3.90x provides near-term liquidity cushion. Zero long-term debt reduces financial leverage and restructuring risk. ChatGPT: Debt-free capital structure reduces financial leverage risk. Current ratio and quick ratio of 3.90x indicate near-term liabilities are manageable.
What are the risks of investing in ALGS?
Claude: Negative operating cash flow of $82.5M with only $18.3M cash on hand implies runway of ~2-3 months without additional capital raises. Net margin of -1106.7% and operating margin of -4024.9% demonstrate business model failure at current stage. ChatGPT: Revenue base is too small to support the cost structure, with operating margin at -4024.9%. Operating cash flow of -$82.50M versus cash of $18.30M implies limited cash runway without new financing.
What is ALGS's revenue and growth?
Aligos Therapeutics, Inc. reported revenue of $2.2M.
Does ALGS pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
Where can I find ALGS SEC filings?
Official SEC filings for Aligos Therapeutics, Inc. (CIK: 0001799448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALGS's EPS?
Aligos Therapeutics, Inc. has a diluted EPS of $-2.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALGS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aligos Therapeutics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALGS stock overvalued or undervalued?
Valuation metrics for ALGS: ROE of -45.2% (sector avg: 15%), net margin of -1,106.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALGS stock in 2026?
Our dual AI analysis gives Aligos Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALGS's free cash flow?
Aligos Therapeutics, Inc.'s operating cash flow is $-82.5M, with capital expenditures of $130.0K. FCF margin is -3,780.1%.
How does ALGS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,106.7% (avg: 12%), ROE -45.2% (avg: 15%), current ratio 3.90 (avg: 2).